{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:41:27Z","timestamp":1784302887380,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) is associated with increased cardiovascular disease (CVD) risk, but differences across phenotypes in Chinese women remain unclear. This study aimed to characterize clinical profiles of PCOS phenotypes, predict CVD risks, and evaluate associations between phenotypes and CVD risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 206 women with PCOS were included from an initial cohort of 211 and classified into four phenotypes according to Rotterdam criteria. Clinical data, laboratory results, and imaging measurements were collected. CVD risks were estimated using the China-PAR model. One-way ANOVA and the Kruskal-Wallis test were used for continuous variables, and Pearson\u2019s chi-square or Fisher\u2019s exact test for categorical variables. Firth logistic regression was employed to assess the association between PCOS phenotypes and CVD risk, and mediation analysis detected the indirect effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 206 patients with PCOS, 104 (50.5%), 36 (17.5%), 19 (9.2%) and 47 (22.8%) were classified as phenotype A, B, C and D. BMI, WC, SBP, and DBP were significantly higher in phenotypes A, B, and C than in D (P&amp;lt;0.05). UA, LDL-C, TG, and HOMA-IR were significantly higher in phenotypes A and B than in D, while HDL-C and ISI-Matsuda were significantly lower (P&amp;lt;0.05). Lifetime CVD risk scores were significantly higher in phenotypes A, B, and C compared with D (P&amp;lt; 0.05), with values of 15.55%, 17.65%, 17.30%, and 9.90%. After adjusting for diet, physical activity, and medication use, phenotypes A (OR 3.18, 95% CI: 1.30-8.84, P = 0.010), B (OR 4.90, 95% CI: 1.58-16.44, P = 0.006), and C (OR 4.67, 95% CI: 1.39-16.64, P = 0.013) were significantly associated with higher odds of high lifetime CVD risk compared with D. The mediating effects of BMI, HOMA-IR, and UA were significant (P&amp;lt; 0.05), with BMI exhibiting the largest mediating effect, accounting for 94.7%, 70.9%, and 42.9% of the total effect in phenotypes A, B, and C compared with D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results demonstrated that more adverse clinical abnormalities and significantly higher CVD risk in women with phenotypes A, B, and C compared with D. BMI, HOMA-IR, and UA play a significantly mediating role between phenotypes and CVD risk. This study suggests that it may be necessary to conduct regular CVD risk assessments for patients with different phenotypes of PCOS, in order to guide early individualized treatment strategies, with a focus on weight and metabolic management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1753316","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:02:57Z","timestamp":1775800977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Differences in clinical characteristics and cardiovascular disease risk prediction among Chinese women with polycystic ovary syndrome phenotypes: a cross-sectional study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ziye","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Xuanwu Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Xuanwu Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Xuanwu Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Xuanwu Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Xuanwu Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Xuanwu Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Xuanwu Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Xuanwu Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, National Health Commission (NHC) Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/jama.2021.19776","article-title":"What is polycystic ovary syndrome","volume":"327","author":"Walter","year":"2022","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2025.08.002","article-title":"Polycystic ovary syndrome: A metabolic disorder with therapeutic opportunities","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tcm.2019.08.010","article-title":"Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention","volume":"30","author":"Osibogun","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320939674","article-title":"Risk of cardiovascular disease for women with polycystic ovary syndrome: Results from a national danish registry cohort study","volume":"28","author":"Oliver-Williams","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9553","article-title":"Polycystic ovary syndrome (pcos) and the risk of coronary heart disease (chd): A meta-analysis","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12958-025-01346-7","article-title":"Cardiovascular disease risk prediction by framingham risk score in women with polycystic ovary syndrome","volume":"23","author":"Amiri","year":"2025","journal-title":"Reprod Biol Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dead110","article-title":"Staying up late increases cardiovascular disease risk in women with polycystic ovary syndrome","volume":"38","author":"Zeng","year":"2023","journal-title":"Hum Reprod"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2018.7162","article-title":"Is there really increased cardiovascular morbidity in women with polycystic ovary syndrome","volume":"27","author":"Carmina","year":"2018","journal-title":"J Womens Health (Larchmt)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae481","article-title":"Risk of type 2 diabetes, masld and cardiovascular disease in people living with polycystic ovary syndrome","volume":"110","author":"Henney","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098","article-title":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23769","article-title":"Diagnosis and treatment of polycystic ovary syndrome","volume":"327","author":"Huddleston","year":"2022","journal-title":"Jama"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf030","article-title":"The pcos phenotype in unselected populations study: Ethnic variation in population-based normative cut-offs for defining hirsutism","volume":"192","author":"Bizuneh","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3969\/j.issn.1000-3614.2025.01.002","article-title":"National clinical practice guideline on obesity management (2024 edition)","volume":"40","author":"Zhang","year":"2025","journal-title":"Chin Circ J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-025-01187-2","article-title":"European guidelines for hypertension in 2024: A comparison of key recommendations for clinical practice","volume":"22","author":"Lauder","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/nu16060763","article-title":"Dietary factors and the risk of depression among women with polycystic ovary syndrome","volume":"16","author":"\u0141agowska","year":"2024","journal-title":"Nutrients"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1249\/01.Mss.0000078924.61453.Fb","article-title":"International physical activity questionnaire: 12-country reliability and validity","volume":"35","author":"Craig","year":"2003","journal-title":"Med Sci Sports Exerc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.7.1087","article-title":"The homeostasis model in the san antonio heart study","volume":"20","author":"Haffner","year":"1997","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1674-5809.2018.06.001","article-title":"Expert consensus on the evaluation methods and their clinical application for insulin resistance","volume":"10","author":"Li","year":"2018","journal-title":"Chin J Diabetes Mellitus"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"Diagnosis and classification of diabetes: Standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.216416","article-title":"Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases","volume":"130","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-3614.2023.03.001","article-title":"Chinese guidelines for lipid management (2023)","volume":"51","author":"Jianjun","year":"2023","journal-title":"Chin J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/nt.0000000000000451","article-title":"Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition)","volume":"17","author":"Zhu","year":"2025","journal-title":"Chin J Diabetes Mellitus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169405","article-title":"Diagnosis and management of the metabolic syndrome","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"B26","unstructured":"China-par risk model"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.030898","article-title":"Genetic predisposition to high blood pressure and lifestyle factors: Associations with midlife blood pressure levels and cardiovascular events","volume":"137","author":"Pazoki","year":"2018","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000677","article-title":"2019 acc\/aha guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3464","article-title":"Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome","volume":"38","author":"Krentowska","year":"2022","journal-title":"Diabetes Metab Res Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.3390\/jcm10173941","article-title":"The associations between sex hormones and lipid profiles in serum of women with different phenotypes of polycystic ovary syndrome","volume":"10","author":"Bizo\u0144","year":"2021","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-014-0500-6","article-title":"Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity","volume":"16","author":"Luque-Ram\u00edrez","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-015-3889-5","article-title":"Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the rotterdam criteria","volume":"293","author":"Jamil","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2019.1613640","article-title":"Correlation of body mass index (bmi), anti-mullerian hormone (amh), and insulin resistance among different polycystic ovary syndrome (pcos) phenotypes - a cross-sectional study","volume":"35","author":"Gupta","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18502\/ijrm.v13i4.6888","article-title":"Prevalence of metabolic syndrome in four phenotypes of pcos and its relationship with androgenic components among Iranian women: A cross-sectional study","volume":"18","author":"Zaeemzadeh","year":"2020","journal-title":"Int J Reprod BioMed"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2018.02.031","article-title":"Metabolic risk assessment of Indian women with polycystic ovarian syndrome in relation to four rotterdam criteria based phenotypes","volume":"224","author":"Tripathy","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4755-12-7","article-title":"A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on rotterdam criteria","volume":"12","author":"Jamil","year":"2015","journal-title":"Reprod Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12916-023-02775-0","article-title":"The hepato-ovarian axis: Genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome","volume":"21","author":"Liu","year":"2023","journal-title":"BMC Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1530\/joe-25-0226","article-title":"Phenotypic variations in polycystic ovary syndrome: Metabolic risks and emerging biomarkers","volume":"267","author":"Ma","year":"2025","journal-title":"J Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2021.04.018","article-title":"Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome","volume":"116","author":"Persson","year":"2021","journal-title":"Fertil Steril"},{"key":"B40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/jcm9030732","article-title":"Body composition, serum concentrations of androgens and insulin resistance in different polycystic ovary syndrome phenotypes","volume":"9","author":"Polak","year":"2020","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16047","article-title":"Correlation of homeostatic model assessment-insulin resistance, anti-mullerian hormone, and bmi in the characterization of polycystic ovary syndrome","volume":"13","author":"Bahadur","year":"2021","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12958-023-01160-z","article-title":"Association of insulin resistance with polycystic ovary syndrome phenotypes and patients' characteristics: A cross-sectional study in Iran","volume":"21","author":"Rahmatnezhad","year":"2023","journal-title":"Reprod Biol Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2023.06.001","article-title":"Cardio-metabolic risk in rotterdam clinical phenotypes of pcos","volume":"85","author":"Mitra","year":"2024","journal-title":"Ann Endocrinol (Paris)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3390\/biomedicines13081997","article-title":"Visceral adiposity index in relation to rotterdam phenotypes of polycystic ovary syndrome","volume":"13","author":"Pluta","year":"2025","journal-title":"Biomedicines"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-12-89","article-title":"The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: A community based study in southwest of Iran","volume":"12","author":"Tehrani","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.3390\/biomedicines11123262","article-title":"Influence of phenotypes on the metabolic syndrome of women with polycystic ovary syndrome over a six-year follow-up in Brazil","volume":"11","author":"Soares-Jr","year":"2023","journal-title":"Biomedicines"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1038\/s41598-017-05717-y","article-title":"Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes","volume":"7","author":"Al-Jefout","year":"2017","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12889-020-10028-5","article-title":"Associations of diet, physical activity and polycystic ovary syndrome in the coronary artery risk development in young adults women's study","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Public Health"},{"key":"B49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12902-022-01208-y","article-title":"Lifestyle management in polycystic ovary syndrome \u2013 beyond diet and physical activity","volume":"23","author":"Cowan","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.822079","article-title":"Cardiovascular risk according to body mass index in women of reproductive age with polycystic ovary syndrome: A systematic review and meta-analysis","volume":"9","author":"Zhuang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tcm.2019.08.010","article-title":"Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention","volume":"30","author":"Osibogun","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex308","article-title":"Insulin resistance in a large cohort of women with polycystic ovary syndrome: A comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes","volume":"32","author":"Tosi","year":"2017","journal-title":"Hum Reprod"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-024-02050-5","article-title":"Polycystic ovary syndrome, insulin resistance, and cardiovascular disease","volume":"26","author":"Dubey","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1356859","article-title":"The positive association between hyperuricemia and polycystic ovary syndrome and analysis of related factors","volume":"15","author":"Gong","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab392","article-title":"Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: A population study","volume":"106","author":"Berni","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12933-018-0680-5","article-title":"Cardiovascular disease in a nationwide population of danish women with polycystic ovary syndrome","volume":"17","author":"Glintborg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1530\/eje-20-0725","article-title":"Body mass index rather than the phenotype impacts precocious ultrasound cardiovascular risk markers in polycystic ovary syndrome","volume":"184","author":"Pandurevic","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0800","article-title":"Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke","volume":"70","author":"Zhu","year":"2021","journal-title":"Diabetes"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1007-5410.2021.02.016","article-title":"Prediction of atherosclerotic cardiovascular disease risk in guangxi zhuang autonomous region","volume":"26","author":"Shicheng","year":"2021","journal-title":"J Clin Cardiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1753316\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:03:05Z","timestamp":1775800985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1753316\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":59,"alternative-id":["10.3389\/fendo.2026.1753316"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1753316","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1753316"}}